Why Is Convatec Up Today?
Convatec Group PLC (LSE:CTEC) shares rose 0.31% to 259p on 16 Nov 2026, leaving the medical products group marginally higher on the London market. Share price movements over a single session are frequently shaped by broader market conditions, changes in investor positioning and sector-wide trading patterns rather than by company-specific developments.
The company's latest interim results, published on 4 August 2026 for the six months to 30 June, showed Revenue of USD 1,232 million, up 4.4%, with organic revenue growth of 5.0% excluding InnovaMatrix and adjusted operating profit up 3.9% to USD 262 million.
Convatec also announced a USD 200 million share buyback and raised its Interim Dividend by 15.4%.
Key Highlights
H1 revenue was USD 1,232 million, with organic growth of 5.0% excluding InnovaMatrix.
Adjusted operating profit rose 3.9% to USD 262 million, and adjusted diluted EPS rose 6.3% to 8.5 US cents.
The interim dividend rose 15.4% to 2.166 US cents, and a USD 200 million buyback was announced.
Full-year guidance was confirmed, with a second-half weighting for growth and a materially higher margin.
About Convatec
Convatec Group PLC, listed as LSE:CTEC, is a global medical products and technologies company focused on chronic care, including advanced wound care, ostomy care, continence and critical care, and infusion care.
For 2025, revenue rose 6.5% to USD 2,439 million, the adjusted operating Margin was 22.3% and adjusted diluted EPS rose 16.0% to 17.6 US cents.
H1 2026 Financial Performance
Adjusted Operating Margin was 21.2%, compared with 21.3% a year earlier, and up 50 basis points at constant currency. Reported operating profit was USD 115 million, compared with USD 179 million, reflecting a USD 69 million non-cash Impairment of InnovaMatrix assets.
Management said new products are launching well and gaining share, with broad-based growth across chronic care categories.
Capital Returns
The interim dividend rose 15.4% to 2.166 US cents, in line with a payout target of 35% to 45% of adjusted net profit. The company announced a USD 200 million share buyback to be completed by the end of 2026, following a USD 300 million buyback last year, and expects Leverage of around 2 times EBITDA by year-end.
Outlook
Convatec confirmed full-year guidance for organic revenue growth of 5.5% to 6.5% excluding InnovaMatrix, an adjusted operating margin of at least 23.0%, double-digit adjusted EPS growth and cash conversion of around 100%. It expects second-half organic growth of 6% to 8%, led by an acceleration in Infusion Care.
The company said the second-half margin will be materially higher than the first half, reflecting its usual second-half revenue weighting, faster Infusion Care growth, reduced InnovaMatrix effects and productivity savings.
Medium-Term Targets
From 2027, Convatec targets annual organic revenue growth of 6% to 8% and an operating margin in the mid-20s, a step up from its previous 5% to 7% growth target.
What Investors Should Watch Next
Readers following LSE:CTEC may focus on Infusion Care growth, new product adoption, margin progression through the second half and progress on the buyback. The full-year 2026 results will provide the next complete update.
Conclusion
Convatec shares rose 0.31% to 259p on 16 Nov 2026, following interim results with adjusted operating profit up 3.9%, a higher dividend, a USD 200 million buyback and confirmed full-year guidance.
Second-half margin progression and new product launches are the main themes for investors.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...